 BOSTON, Feb. 04, 2021 GLOBE NEWSWIRE -- Inozyme Pharma, Inc. Nasdaq: INZY, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced the appointment of Deborah Wenkert, M.D. as senior vice president and chief medical officer, effective February 2, 2021. 